Miami, FLA. Stock Market Alert's performance stock list includes: Sunwin International Neutraceuticals, Inc. (OTCBB: SUWN), Del Global Technologies Corp. (OTCBB: DGTC), MedaSorb Technologies Corporation (OTCBB: MSBT) and GetFugu, Inc. (OTCBB: GFGU).
This morning, Sunwin International Neutraceuticals, Inc. (OTCBB: SUWN) and WILD Flavors Inc., announced today that they have developed more than 30 proprietary natural taste modifications dedicated to Stevia extracts sold by Sunwin and WILD Flavors, one of the top natural food and beverage development firms worldwide.
These and other taste topics will be discussed at the upcoming Stevia World Europe 2009 Conference to be held in Frankfurt, Germany, on November 18, 2009. Stevia World Europe 2009 is a showcase of the who's who in the Stevia sector, including top stevia growers, refiners, traders, key stevia organizations, government officials, scientists and investors.
Sunwin and WILD Flavors offer multiple stevia grades meeting GRAS (Generallly Recognized As Safe) and WHO (World Health Organization) specifications as well as the new French requirements, which can be paired with the natural taste modifications to provide the best flavor profile in specific foods while meeting or beating targeted cost in use requirements. The modifiers are designed for tabletop sweeteners, a wide variety of beverages, sauces (both sweet and savory), candy, gum, cereal, baked goods, yogurt and many other applications. The companies currently sell into a number of markets including enhanced waters, functional beverages, and reduced calorie juices.
"These taste modifiers make a great sweetener even better," said Greg Horn, Senior Director of Sweetener Technology at WILD Flavors. "The natural tastes make Stevia usable in a broader array of products by offering a natural, low-calorie or no-calorie sweetening system capable of achieving specific taste profiles. These proprietary modifiers were developed through WILD Flavors' extensive experience in natural products for the consumer goods industry and are available only through WILD Flavors for Sunwin's OnlySweet Stevia extracts. Together they create great tastes at lower costs, including opening the ability to use less expensive Stevia extracts without compromising taste."
As part of Stevia World Europe 2009 Horn will present a lecture titled "Developments in Flavor Masking and Sweetness Enhancement Technologies" expanding on WILD's expertise in the development of successful consumer products and how the use of Stevia adds new market opportunity in natural low- and no-calorie products.
The stock closed Friday at around Twenty cents a share a share.
For an in-depth profile of Sunwin International Neutraceuticals, visit http://wallstreetenews.com/view-company-profiles.php?profile=SUWN-072909.
To receive FREE Mobile Stock Alerts formatted especially for your cell phone, text the word "press" in the subject line to 68494.
For more information, please visit www.WallStreetNewsAlert.com and you can also follow Wall Street News Alerts on Twitter at http://twitter.com/wsna
Del Global Technologies Corp. (OTCBB: DGTC) up 22.5% on 5.4 million shares traded.
On Nov 12, 2009 Del Global Technologies Corp. and United Marketing Group recently announced they have entered into an Agreement in Principle to transfer certain assets and the product lines of Del Medical Imaging from Del Global to UMG. It is the goal of the parties to have the transaction completed prior to the 2009 Radiological Society of North America (RSNA) trade show beginning at the end of this month. This strategic acquisition adds the heritage and quality of the Del Medical X-ray products to the already robust product portfolio of UMG.
"UMG intends to continue to run Del Medical as a wholly-owned subsidiary, enhance the existing product line and maintain the collective current channels of distribution. We are proud to bring the Del Medical reputation under the UMG umbrella. We will continue to offer the same quality and reliability of Del Medical products that our customers have come to expect," says Toufic Lorenzo, President & CEO of United Marketing Group.
"We are pleased that we have found a home with UMG for the Del Medical U.S. imaging business that will provide for it to grow and prosper. The transaction does not include our Villa subsidiary in Italy," said John Quicke, President and CEO of Del Global. He added, "After completion of this transaction Del Global will focus its efforts on growing Villa in the international imaging markets and the power supply business through its RFI subsidiary."
The transaction is subject to execution of a definitive agreement among the parties and approval of the Boards of Directors of Del Global and UMG. No assurances can be given that a definitive agreement will be executed.
ABOUT DEL GLOBAL TECHNOLOGIES: Del Global Technologies Corp. is primarily engaged in the design, manufacture and marketing of high performance diagnostic imaging systems for medical, dental and veterinary applications through the Del Medical Systems Group. Through its U.S. based Del Medical Imaging Corp. and Milan, Italy based Villa Sistemi Medicali S.p.A. subsidiaries, the Company offers a broad portfolio of general radiographic, radiographic/fluoroscopic, portable x-ray and digital radiographic systems to the global marketplace. Through its RFI subsidiary, Del Global manufactures proprietary high-voltage power conversion subsystems including electronic filters, high voltage capacitors, pulse modulators, transformers and reactors, and a variety of other products designed for industrial, medical, military and other commercial applications. The Company's web site is www.delglobal.com.
MedaSorb Technologies Corporation (OTCBB: MSBT) up 15.8% on 1.8 million shares traded. On Nov 13, 2009 MedaSorb Technologies Corporation and its wholly-owned subsidiary, CytoSorbents, Inc., recently announced it provided an update of its clinical program. Dr. Phillip Chan, Chief Executive Officer, stated, "As we welcome many new investors to the company, I wanted to give a brief update on our European Sepsis Trial. As many know, MedaSorb has developed a powerful blood purification technology platform that can remove drugs, proteins, toxins and other substances from blood and physiologic fluids. With our flagship product CytoSorb(TM), we are currently conducting one of the largest randomized, controlled clinical trials of its kind to treat patients with severe sepsis and respiratory failure by directly attempting to reduce 'cytokine storm' that often leads to organ failure and death in this disease. Severe sepsis and cytokine storm are particularly relevant today, as they have likely contributed to the deaths of many people infected with the H1N1 swine influenza virus in countries across the world. By potentially reducing these toxic cytokine levels in the blood, we hope CytoSorb(TM) can prevent and limit organ injury, giving patients time to heal and recover."
Preliminary Clinical Data from Sepsis Pilot Study We previously discussed that the first 22 patients in our European Sepsis Trial were categorized into a pilot study. Treatment was well-tolerated in this study and there were no serious device related adverse events. We currently have fully-monitored, completed data sets on 13 of these patients. These represent all twelve patients from a major, well-known, academic university hospital as well as one patient from another large clinical trial site. Seven of these patients were treated with CytoSorb(TM) and standard of care therapy, while six others were in the control group receiving standard of care therapy alone. We are encouraged that an analysis of the data demonstrates improvements in many of the secondary and exploratory endpoints of the trial in the treatment group compared to the control group including: 28-day and 60-day all cause mortality, Ventilator free days, Pace of ventilator weaning, Organ failure scores, Vasopressor use, Days in the intensive care unit.
These objective endpoints in the treatment of severe sepsis are important. First, improvements in these key outcomes are difficult to accomplish but are directly associated with improved patient outcome and survival. Secondly, these are parameters used by critical care physicians to judge how patients are doing and are predictors of length of stay and cost of stay in the intensive care unit. Lastly, improvements in these criteria are consistent with how CytoSorb(TM) is intended to work. Cytokine storm-induced organ failure such as acute respiratory distress syndrome requiring mechanical ventilation, hemodynamic shock requiring vasopressors, and renal failure requiring dialysis is well-documented. Reduction of cytokine storm by CytoSorb(TM) is intended to reduce organ failure and the need for these types of interventions and we are pleased to see this correlation.
MedaSorb Technologies Corporation, and its operating subsidiary CytoSorbents, is a therapeutic device company in clinical trials to treat severe sepsis, often called "overwhelming infection," with a novel blood purification device called CytoSorb(TM).
GetFugu, Inc. (OTCBB: GFGU) up 5.2% on 841,000 shares traded.
On Nov 13, 2009 GetFugu, Inc. recently announced that it has appointed several key directors and executives to the Board of Directors and senior management team. In addition, the Company has updated its corporate governance policies and obtained Standard & Poor's listing.
GetFugu has added five independent directors to the board, Michael Jay Solomon as Chairman; and Alan J. Bailey, Donald A. Kurz, Michael J. O'Connor and Chuck Timpe as Directors.
About GetFugu, Inc.: GetFugu is the first technology architect to provide a carrier agnostic, platform agnostic mobile search platform. GetFugu will change the way people access the web with their mobile phones. It is designed to encourage use of its applications by integrating the mobile phone's core strengths (image recognition, voice recognition, location recognition) into a single customizable application. Additionally, GetFugu offers the only mobile ecommerce platform available worldwide today. The GetFugu platform will soon be available for 97% of the mobile phones available (over 3.3 billion handsets) worldwide.
This advertisement is provided by Wall Street Enews, a division of Stock Market Alerts LLC, an electronic broadcaster and publisher of this release, and hereafter referred to as "the company". The company also maintains a contractual, working relationship with Wall Street Capital Funding LLC. and its' Wall Street News Alert brand. For current services performed for Sunwin International Neutraceuticals, Inc. (OTCBB: SUWN), China Direct Industries, Inc. ("China Direct Industries"), Dragon Capital Group Corp, China America Holdings, China Armco Metals, Inc. and Dragon International Group Corp., the company has been compensated a total of Three Hundred Thousand Dollars (Two Hundred and Fifty Thousand dollars for current services and Fifty Thousand dollars for previous services) by China Direct Investments Inc., a Florida corporation, and a wholly owned subsidiary of China Direct. The company does not hold any shares of the stock. Because the company received compensation for its services, there is an inherent conflict of interest in the company statements and opinions and such statements and opinions cannot be considered independent.
The information contained in this press release is for informational purposes only, and not to be construed as an offer to sell or solicitation of an offer to buy any security. The company makes no representation or warranty relating to the validity of the facts presented nor does the company represent or warrant that all material facts necessary to make an investment decision are presented above. Stock Market Alerts LLC is an advertising company and therefore, this release should be viewed for informational purposes only.
The company relies exclusively on information gathered on the public company, such as public filings, press releases and its web sites. Investors should use the advertising information contained in this release as a starting point for conducting additional research on the public company in order to allow the investor to form his or her own opinion regarding the public company. Factual statements contained in this publication are made as of the date stated and they are subject to change without notice. The company is not a registered investment adviser, broker or a dealer.
Investing in the public company that this release is providing service for should be reviewed as speculative and a high-risk and may result in the loss of some or all of any investment.
This release may contain statements that constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended. The words "may," "would," "will," "expect," "estimate," "anticipate," "believe," "intend," and similar expressions and variations thereof are intended to identify forward-looking statements.
((Comments on this story may be sent to info@m2.com))
